Synta Pharmaceuticals Strengthens Management Team With New Scientific and Business Appointments

Oct 15, 2004, 01:00 ET from Synta Pharmaceuticals Corp.

    LEXINGTON, Mass., Oct. 15 /PRNewswire/ -- Synta Pharmaceuticals Corp., an
 emerging pharmaceutical company, today announced the following appointments:
 Ninad Deshpanday, Ph.D. as Vice President, Drug Product Development; Patricia
 McCall as Vice President, Human Resources; and Cynthia Clayton as Director,
 Investor Relations and Corporate Communications.
     Ninad Deshpanday, Ph.D., Vice President, Drug Product Development
     Dr. Deshpanday comes to Synta from Cardinal Health where he was the
 Technical Business Director responsible for both business development and
 strategic technical functions within the Pharmaceutics division.  Dr.
 Deshpanday has over 14 years' experience in product development and drug
 delivery technology and has led the product development efforts behind
 numerous successful filings with regulatory agencies in the U.S., Europe, and
 Japan, across multiple therapeutic areas including dermatology, cardiology,
 and cancer.  Prior to Cardinal Health, Dr. Deshpanday held positions at
 aaiPharma, TheraTech, Inc., and Procter & Gamble Pharmaceuticals. Dr.
 Deshpanday received both his B.S. and Masters in Pharmacy from Gujarat
 University in India, and his Ph.D. in Pharmacy from the University of South
     "We have made significant progress over the past year advancing our
 clinical pipeline," said Keizo Koya, Ph.D., Senior Vice President, Drug
 Development at Synta. "Ninad's expertise in manufacturing, formulation, and
 product development, and his experience with multiple investigational new drug
 submissions and new drug applications will be invaluable to Synta as we
 continue to advance our pipeline to commercial readiness."
     Patricia McCall, Vice President, Human Resources
     Ms. McCall brings to Synta nearly 25 years' experience as a human
 resources executive.  Most recently, Ms. McCall held the position of Vice
 President, Human Resources for ACMI Corporation, a 1,000-employee medical
 device firm, where she led the human resource related efforts to transform
 that organization into a growth company.  Ms. McCall also served as
 International Human Resource Director for Energia Global International.  Prior
 to that, Ms. McCall spent 19 years with Hewlett-Packard's Healthcare Solutions
 Group in areas of increasing responsibility including Human Resources
 Director.  Ms. McCall received her B.S. in Business Administration from
 Emmanuel College in Boston.
     "Tricia joins our team at a crucial time in Synta's growth," said Safi
 Bahcall, Ph.D., President and Chief Executive Officer of Synta. "Her extensive
 experience in all aspects of strategic and operational human resources
 management will be important as we transition from a discovery-focused and
 early clinical operation, to a fully integrated, commercial drug development
 company.  Tricia will lead the effort to preserve the spirit of our core
 values and guiding principles as we grow -- our focus on quality of science,
 speed of execution, and passion for improving the lives of patients.  In
 addition, she will be continuing our mission of attracting and developing the
 world-class talent and expertise we need to achieve our goals."
     Cynthia Clayton, Director, Investor Relations and Corporate Communications
 Ms. Clayton joins Synta from Millennium Pharmaceuticals where she was the
 Senior Manager, Investor and Corporate Communications.  At Millennium, she
 worked as part of an award-winning team driving the communications initiatives
 of an established, product-driven biopharmaceutical company.  Prior to joining
 Millennium, Ms. Clayton served as Manager, Corporate Communications for Curis,
 an earlier-stage biotechnology company that underwent a three-way merger to
 emerge as a public company.  Ms. Clayton earned her B.A. in Communications
 from the University of Hartford in Connecticut.
     "This is a very exciting and critical time for Synta as we continue to
 grow and add key functions company-wide," said John McCarthy, Senior Vice
 President, Corporate Development and Chief Financial Officer at Synta.
 "Cynthia's combined set of experiences will be an important asset to the team
 as we begin to reach out to the audiences interested in learning more about
 Synta's differentiated business strategy, exciting and diverse clinical
 programs, and compelling career opportunities."
     About Synta
     Synta Pharmaceuticals is an emerging pharmaceutical company focused on
 discovering, developing, and commercializing products for extending and
 enhancing the lives of patients with severe medical conditions.  Synta has a
 diverse pipeline of first-in-class, small-molecule drug candidates for the
 treatment of major immune disorders and cancers, with two lead products in
 multiple Phase 2 clinical trials.  All clinical candidates were developed
 internally, and Synta fully owns all rights in all indications and markets.
 Synta developed as a buyout of the U.S. subsidiary of a large Japanese
 pharmaceutical company in 2002 and, as a result, has an experienced and
 fully integrated drug discovery and development operation.  Synta has raised
 over $128 million in private financing in the last three years to support its
 plans.  For more information, please see
      Synta Pharmaceuticals Corp.      Euro RSCG Life NRP
      Cynthia Clayton                  Robert Stanislaro
      Director, Investor Relations     Senior Account Executive
      and Corporate Communications     (212) 845-4268
      (781) 541-7125         

SOURCE Synta Pharmaceuticals Corp.